CRISPR-based drugs face tricky manufacturing problem

2-3-2019 df b aeb d bf crispr
Image credit: Bryan Satalino

There are two key challenges in delivering a CRISPR-Cas9 therapy so it is effective in the body: It must be delivered to a specific tissue, and it must also be delivered to the cells within that tissue.

As the gene-editing community focuses on the extraordinary promise of editing somatic cells to address profound unmet medical needs and its potential for alleviating human suffering, we also need to solve the more prosaic problems of delivery and manufacturing.

Companies that advance to clinical trials will require a much larger quantity of experimental drugs. Two manufacturing questions face these companies: If we started our manufacturing program in house, should we continue down that road and build our own manufacturing facility? If we started with a contract manufacturing organization, should we continue working with it or bring manufacturing in-house and build our own facility?

Related article:  CRISPR gene editing knocks out viruses responsible for billions of dollars in crop losses

The right answer is tricky enough to qualify as a business school case study. Building manufacturing capacity is frighteningly expensive. And it won’t be ready for three to five years after you’ve made the decision to green light the project. So making the right decision requires an extraordinary amount of capital, foresight, and luck.

Read full, original post: CRISPR-Cas9 commercialization may be slowed by delivery and manufacturing challenges

Outbreak Daily Digest
Biotech Facts & Fallacies
Talking Biotech
Genetics Unzipped
Video: Test everyone – Slovakia goes its own way to control COVID

Video: Test everyone – Slovakia goes its own way to control COVID

As Europe sees record coronavirus cases and deaths, Slovakia is testing its entire adult population. WSJ's Drew Hinshaw explains how ...
mag insects image superjumbo v

Disaster interrupted: Which farming system better preserves insect populations: Organic or conventional?

A three-year run of fragmentary Armageddon-like studies had primed the journalism pumps and settled the media framing about the future ...
dead bee desolate city

Are we facing an ‘Insect Apocalypse’ caused by ‘intensive, industrial’ farming and agricultural chemicals? The media say yes; Science says ‘no’

The media call it the “Insect Apocalypse”. In the past three years, the phrase has become an accepted truth of ...
globalmethanebudget globalcarbonproject cropped x

Infographic: Cows cause climate change? Agriculture scientist says ‘belching bovines’ get too much blame

A recent interview by Caroline Stocks, a UK journalist who writes about food, agriculture and the environment, of air quality ...
organic hillside sweet corn x

Organic v conventional using GMOs: Which is the more sustainable farming?

Many consumers spend more for organic food to avoid genetically modified products in part because they believe that “industrial agriculture” ...
benjamin franklin x

Are most GMO safety studies funded by industry?

The assertion that biotech companies do the research and the government just signs off on it is false ...

Environmental Working Group: EWG challenges safety of GMOs, food pesticide residues

Known by some as the "Environmental Worrying Group," EWG lobbies for tighter GMO legislation and famously puts out annual "dirty dozen" list of fruits and ...
m hansen

Michael Hansen: Architect of Consumers Union ongoing anti-GMO campaign

Michael K. Hansen (born 1956) is thought by critics to be the prime mover behind the ongoing campaign against agricultural biotechnology at Consumer Reports. He is an ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend